dry%20eye%20syndrome
DRY EYE SYNDROME

Dry eye syndrome is a clinical condition wherein the patient experiences ocular and conjunctival irritation due to decreased tear production and/or excessive tear evaporation.
It is associated with increased osmolarity of the tear film and inflammation of the ocular surface.

Goal of treatments are to relieve symptoms of patients, to improve visual acuity & quality of life of patients, to restore ocular surface & tear film to normal homeostatic state and to correct the underlying defect.

Follow Up

  • The patient is advised to follow up, in order to assess their response to therapy, if there is a need to alter or adjust the treatment & to monitor structural ocular damage, as well as to provide reassurance
  • Frequency & extent of follow-up will depend on the severity of the disease, therapeutic approach & response to therapy

Counselling

  • Clinicians should provide their patients w/ proper instructions for their therapeutic regimens, as well as caution them about LASIK, as this may worsen their dry eye condition
    • May refer their patients to an appropriate specialist, if there are other causes or underlying conditions that would contribute to having dry eye 
  • Patients should be educated about the chronic nature of the disease & its process
    • Their compliance, understanding of the disease, risks for structural changes should periodically be reassessed
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.